CORNEAT VISION

CorNeat Vision leverages synthetic biology to introduce implants that address unresolved ophthalmic challenges in the areas of corneal blindness, ocular trauma, glaucoma, hypotony and epiphora (tearing). As of today, we have successfully developed an artificial cornea and an artificial sclera.

NEWS - CORNEAT

CorNeat Vision's Synthetic Cornea Approved for First-in-Human Implantation. New Hope for the Corneally Blind Provides Definitive Protection from COVID-19 Transmission. July 2020. Read More.

CORNEAT KPRO

The CorNeat KPro is an artificial cornea, Keratoprosthesis, which provides a long-lasting medical solution for corneal blindness, pathology and injury. CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue.

TEAM - CORNEAT

Our mission is to promote health and equality worldwide through innovative biomimetic medical solutions that are widely accessible. Our goal at CorNeat Vision is to innovate and grow, as well as leverage the power of partnerships to introduce biomimetic implants that aim to permanently resolve medical and surgical challenges in diversified therapeutic fields.

OUR TECHNOLOGY & IP

Our Technology. Our core technology consists of a biocompatible, nondegradable biomimetic material that imitates the micro-structure of the human Extracellular Matrix (ECM); the collagen mesh providing the structural and biochemical support to surrounding cells. Unlike scaffolds and other collagen matrices, which are used for tissue

repair and

CORNEAT KPRO

The CorNeat KPro is an artificial cornea, which provides a long-lasting medical solution for corneal blindness, pathology and injury. The CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue.

COMMERCIAL PARTNERS

Corneat Vision is establishing its global presence through selected authorized distributors. Our distribution partners shall provide high standards of service, customer support and regulatory compliance. If your company would like to become our distributor, please take our survey and leave your contact details using the link below. R. DOYLE STULTING, MD, PHD R. Doyle Stulting, MD, PhD. United States. Dr. Stulting is the Co-Founder of the Stulting Research Center, a pioneer in corneal disease research and LASIK, and serves as the Director of Corneal Disease and Research at Woolfson Eye Institute. With an illustrious career spanning more than 30 years, his basic research efforts have

created deeper

GILAD LITVIN, MD

Gilad Litvin, MD. Co-Founder, Chairman, Chief Medical Officer. Dr. Litvin is a graduate of The Hebrew University Medical School in Jerusalem. He completed his residency at the Meir Medical Center in Kfar Saba. He worked as a fellow for two years, specializing in retinal surgery, and completed three years of post-graduate studies in 4TH CHINA-ISRAEL INNOVATION AND ENTREPRENEURSHIP CONTEST 4th China-Israel Innovation and Entrepreneurship Contest. During the 4th China-Israel Innovation and Entrepreneurship Contest, held by the Israel Innovation Authority, CorNeat Vision won the life science startup contest out of 13 Israeli life science startups, and made it to the finals. Almog Aley-Raz, CorNeat Vision’s CEO & VP R&D, gave

CORNEAT VISION

CorNeat Vision leverages synthetic biology to introduce implants that address unresolved ophthalmic challenges in the areas of corneal blindness, ocular trauma, glaucoma, hypotony and epiphora (tearing). As of today, we have successfully developed an artificial cornea and an artificial sclera.

NEWS - CORNEAT

CorNeat Vision's Synthetic Cornea Approved for First-in-Human Implantation. New Hope for the Corneally Blind Provides Definitive Protection from COVID-19 Transmission. July 2020. Read More.

CORNEAT KPRO

The CorNeat KPro is an artificial cornea, Keratoprosthesis, which provides a long-lasting medical solution for corneal blindness, pathology and injury. CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue.

TEAM - CORNEAT

Our mission is to promote health and equality worldwide through innovative biomimetic medical solutions that are widely accessible. Our goal at CorNeat Vision is to innovate and grow, as well as leverage the power of partnerships to introduce biomimetic implants that aim to permanently resolve medical and surgical challenges in diversified therapeutic fields.

OUR TECHNOLOGY & IP

Our Technology. Our core technology consists of a biocompatible, nondegradable biomimetic material that imitates the micro-structure of the human Extracellular Matrix (ECM); the collagen mesh providing the structural and biochemical support to surrounding cells. Unlike scaffolds and other collagen matrices, which are used for tissue

repair and

CORNEAT KPRO

The CorNeat KPro is an artificial cornea, which provides a long-lasting medical solution for corneal blindness, pathology and injury. The CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue.

COMMERCIAL PARTNERS

Corneat Vision is establishing its global presence through selected authorized distributors. Our distribution partners shall provide high standards of service, customer support and regulatory compliance. If your company would like to become our distributor, please take our survey and leave your contact details using the link below. R. DOYLE STULTING, MD, PHD R. Doyle Stulting, MD, PhD. United States. Dr. Stulting is the Co-Founder of the Stulting Research Center, a pioneer in corneal disease research and LASIK, and serves as the Director of Corneal Disease and Research at Woolfson Eye Institute. With an illustrious career spanning more than 30 years, his basic research efforts have

created deeper

GILAD LITVIN, MD

Gilad Litvin, MD. Co-Founder, Chairman, Chief Medical Officer. Dr. Litvin is a graduate of The Hebrew University Medical School in Jerusalem. He completed his residency at the Meir Medical Center in Kfar Saba. He worked as a fellow for two years, specializing in retinal surgery, and completed three years of post-graduate studies in 4TH CHINA-ISRAEL INNOVATION AND ENTREPRENEURSHIP CONTEST 4th China-Israel Innovation and Entrepreneurship Contest. During the 4th China-Israel Innovation and Entrepreneurship Contest, held by the Israel Innovation Authority, CorNeat Vision won the life science startup contest out of 13 Israeli life science startups, and made it to the finals. Almog Aley-Raz, CorNeat Vision’s CEO & VP R&D, gave

CORNEAT VISION

CorNeat Vision leverages synthetic biology to introduce implants that address unresolved ophthalmic challenges in the areas of corneal blindness, ocular trauma, glaucoma, hypotony and epiphora (tearing). As of today, we have successfully developed an artificial cornea and an artificial sclera.

CORNEAT EVERPATCH

The CorNeat EverPatch (scleral patch) is the first inert, synthetic and non-degradable tissue substitute for use in ophthalmic surgeries. CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma

drainage devices.

OUR TECHNOLOGY & IP

Our Technology. CorNeat Vision’s core technology consists of a biocompatible non-degradable biomimetic material that imitates the micro-structure of the human extracellular matrix (ECM) which is the collagen mesh that provides the structural and biochemical support to surrounding cells. Unlike scaffolds and other collagen matrices which

are

EVENTS - CORNEAT VISION The CorNeat KPro is a nanotechnology-based solution which will bring new hope to millions of blind and visually-impaired people

CORNEAT ESHUNT

The CorNeat eShunt is determined to revolutionize the treatment of glaucoma. It is designed to regulate the intraocular pressure and addresses the shortcomings of existing solutions. Using advanced materials, the eShunt inlet, which is placed in the anterior chamber angle, mimics the trabecular mesh CORNEAT KPRO ANIMATION I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication channels CONTACT | CORNEAT VISION | BIOMIMETIC IMPLANTS AND TECHNOLOGY info@corneat.com 4 Hasheizaf St. Raanana, Israel I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication

channels

SEEING AGAIN!

I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication channels EDWARD J. HOLLAND, MD Edward J. Holland, M.D. is the Director of Cornea Services at Cincinnati Eye Institute and Professor of Ophthalmology at the University of Cincinnati. He attended the Loyola-Stritch School of Medicine in Chicago and trained in Ophthalmology at the University of Minnesota. Dr. Holland completed a fellowship in Cornea and External Disease at the University of Iowa, and a second fellowship in DAVID ROOTMAN, MD, FRCSC Professor David Rootman has extensive qualifications placing him within an elite circle of top corneal specialist surgeons. Dr. Rootman has been a board member of the Cornea Society (until 2008) and on staff at the University Health Network and the Hospital for Sick Children. At Toronto Western Hospital, he performs over 150 corneal transplants annually and deals with some of the most complex

CORNEAT VISION

CorNeat Vision leverages synthetic biology to introduce implants that address unresolved ophthalmic challenges in the areas of corneal blindness, ocular trauma, glaucoma, hypotony and epiphora (tearing). As of today, we have successfully developed an artificial cornea and an artificial sclera.

CORNEAT KPRO

The CorNeat KPro is an artificial cornea, Keratoprosthesis, which provides a long-lasting medical solution for corneal blindness, pathology and injury. CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue.

NEWS - CORNEAT

CorNeat Vision's Synthetic Cornea Approved for First-in-Human Implantation. New Hope for the Corneally Blind Provides Definitive Protection from COVID-19 Transmission. July 2020. Read More.

TEAM - CORNEAT

Our mission is to promote health and equality worldwide through innovative biomimetic medical solutions that are widely accessible. Our goal at CorNeat Vision is to innovate and grow, as well as leverage the power of partnerships to introduce biomimetic implants that aim to permanently resolve medical and surgical challenges in diversified therapeutic fields.

OUR TECHNOLOGY & IP

Our Technology. Our core technology consists of a biocompatible, nondegradable biomimetic material that imitates the micro-structure of the human Extracellular Matrix (ECM); the collagen mesh providing the structural and biochemical support to surrounding cells. Unlike scaffolds and other collagen matrices, which are used for tissue

repair and

CORNEAT KPRO

The CorNeat KPro is an artificial cornea, which provides a long-lasting medical solution for corneal blindness, pathology and injury. The CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue.

COMMERCIAL PARTNERS

Corneat Vision is establishing its global presence through selected authorized distributors. Our distribution partners shall provide high standards of service, customer support and regulatory compliance. If your company would like to become our distributor, please take our survey and leave your contact details using the link below.

CORNEAT VISION

I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication channels R. DOYLE STULTING, MD, PHD R. Doyle Stulting, MD, PhD. United States. Dr. Stulting is the Co-Founder of the Stulting Research Center, a pioneer in corneal disease research and LASIK, and serves as the Director of Corneal Disease and Research at Woolfson Eye Institute. With an illustrious career spanning more than 30 years, his basic research efforts have

created deeper

GILAD LITVIN, MD

Gilad Litvin, MD. Co-Founder, Chairman, Chief Medical Officer. Dr. Litvin is a graduate of The Hebrew University Medical School in Jerusalem. He completed his residency at the Meir Medical Center in Kfar Saba. He worked as a fellow for two years, specializing in retinal surgery, and completed three years of post-graduate studies in

CORNEAT VISION

CorNeat Vision leverages synthetic biology to introduce implants that address unresolved ophthalmic challenges in the areas of corneal blindness, ocular trauma, glaucoma, hypotony and epiphora (tearing). As of today, we have successfully developed an artificial cornea and an artificial sclera.

CORNEAT KPRO

The CorNeat KPro is an artificial cornea, Keratoprosthesis, which provides a long-lasting medical solution for corneal blindness, pathology and injury. CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue.

NEWS - CORNEAT

CorNeat Vision's Synthetic Cornea Approved for First-in-Human Implantation. New Hope for the Corneally Blind Provides Definitive Protection from COVID-19 Transmission. July 2020. Read More.

TEAM - CORNEAT

Our mission is to promote health and equality worldwide through innovative biomimetic medical solutions that are widely accessible. Our goal at CorNeat Vision is to innovate and grow, as well as leverage the power of partnerships to introduce biomimetic implants that aim to permanently resolve medical and surgical challenges in diversified therapeutic fields.

OUR TECHNOLOGY & IP

Our Technology. Our core technology consists of a biocompatible, nondegradable biomimetic material that imitates the micro-structure of the human Extracellular Matrix (ECM); the collagen mesh providing the structural and biochemical support to surrounding cells. Unlike scaffolds and other collagen matrices, which are used for tissue

repair and

CORNEAT KPRO

The CorNeat KPro is an artificial cornea, which provides a long-lasting medical solution for corneal blindness, pathology and injury. The CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue.

COMMERCIAL PARTNERS

Corneat Vision is establishing its global presence through selected authorized distributors. Our distribution partners shall provide high standards of service, customer support and regulatory compliance. If your company would like to become our distributor, please take our survey and leave your contact details using the link below.

CORNEAT VISION

I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication channels R. DOYLE STULTING, MD, PHD R. Doyle Stulting, MD, PhD. United States. Dr. Stulting is the Co-Founder of the Stulting Research Center, a pioneer in corneal disease research and LASIK, and serves as the Director of Corneal Disease and Research at Woolfson Eye Institute. With an illustrious career spanning more than 30 years, his basic research efforts have

created deeper

GILAD LITVIN, MD

Gilad Litvin, MD. Co-Founder, Chairman, Chief Medical Officer. Dr. Litvin is a graduate of The Hebrew University Medical School in Jerusalem. He completed his residency at the Meir Medical Center in Kfar Saba. He worked as a fellow for two years, specializing in retinal surgery, and completed three years of post-graduate studies in

NEWS - CORNEAT

CorNeat Vision's Synthetic Cornea Approved for First-in-Human Implantation. New Hope for the Corneally Blind Provides Definitive Protection from COVID-19 Transmission. July 2020. Read More. INTRO | CORNEAT VISION | BIOMIMETIC IMPLANTS AND TECHNOLOGY CorNeat Vision leverages synthetic biology to introduce implants that address unresolved ophthalmic challenges in the areas of corneal blindness, ocular trauma, glaucoma, hypotony and epiphora (tearing). As of today, we have successfully developed an artificial cornea and an artificial sclera.

OUR TECHNOLOGY & IP

Our Technology. CorNeat Vision’s core technology consists of a biocompatible non-degradable biomimetic material that imitates the micro-structure of the human extracellular matrix (ECM) which is the collagen mesh that provides the structural and biochemical support to surrounding cells. Unlike scaffolds and other collagen matrices which

are

CORNEAT EVERPATCH

The CorNeat EverPatch (scleral patch) is the first inert, synthetic and non-degradable tissue substitute for use in ophthalmic surgeries. CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma

drainage devices.

CORNEAT ESHUNT

CorNeat eShunt. The CorNeat eShunt is determined to revolutionize the treatment of glaucoma. It is designed to regulate the intraocular pressure and addresses the shortcomings of existing solutions. Using advanced materials, the CorNeat eShunt inlet, which is placed in the anterior chamber angle, mimics the trabecular meshwork’s function in EVENTS - CORNEAT VISION The CorNeat KPro is a nanotechnology-based solution which will bring new hope to millions of blind and visually-impaired people CONTACT | CORNEAT VISION | BIOMIMETIC IMPLANTS AND TECHNOLOGY info@corneat.com 4 Hasheizaf St. Raanana, Israel I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication

channels

CORNEAT ESHUNT

The CorNeat eShunt is determined to revolutionize the treatment of glaucoma. It is designed to regulate the intraocular pressure and addresses the shortcomings of existing solutions. Using advanced materials, the eShunt inlet, which is placed in the anterior chamber angle, mimics the trabecular mesh CORNEAT KPRO ANIMATION I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication channels

SEEING AGAIN!

I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication channels

CORNEAT VISION

CorNeat Vision leverages synthetic biology to introduce implants that address unresolved ophthalmic challenges in the areas of corneal blindness, ocular trauma, glaucoma, hypotony and epiphora (tearing). As of today, we have successfully developed an artificial cornea and an artificial sclera.

NEWS - CORNEAT

Tune in to this episode of The Joel Show and listen to an interview with Dr. Gilad Litvin and Almog Aley-Raz, speaking in greater detail about CorNeat Vision’s

CORNEAT KPRO

The CorNeat KPro is an artificial cornea, Keratoprosthesis, which provides a long-lasting medical solution for corneal blindness, pathology and injury. CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue.

TEAM - CORNEAT

Our mission is to promote health and equality worldwide through innovative biomimetic medical solutions that are widely accessible. Our goal at CorNeat Vision is to innovate and grow, as well as leverage the power of partnerships to introduce biomimetic implants that aim to permanently resolve medical and surgical challenges in diversified therapeutic fields.

CORNEAT EVERPATCH

The CorNeat EverPatch (scleral patch) is the first inert, synthetic and non-degradable tissue substitute for use in ophthalmic surgeries. CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma

drainage devices.

COMMERCIAL PARTNERS

Corneat Vision is establishing its global presence through selected authorized distributors. Our distribution partners shall provide high standards of service, customer support and regulatory compliance. If your company would like to become our distributor, please take our survey and leave your contact details using the link below. CORNEAT KPRO ANIMATION I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication channels R. DOYLE STULTING, MD, PHD Dr. Stulting is the Co-Founder of the Stulting Research Center, a pioneer in corneal disease research and LASIK, and serves as the Director of Corneal Disease and Research at Woolfson Eye Institute. With an illustrious career spanning more than 30 years, his basic research efforts have created deeper understanding of the mechanisms of corneal transplant rejection, herpetic ocular disease and EDWARD J. HOLLAND, MD Edward J. Holland, M.D. is the Director of Cornea Services at Cincinnati Eye Institute and Professor of Ophthalmology at the University of Cincinnati. He attended the Loyola-Stritch School of Medicine in Chicago and trained in Ophthalmology at the University of Minnesota. Dr. Holland completed a fellowship in Cornea and External Disease at the University of Iowa, and a second fellowship in

GILAD LITVIN, MD

Gilad Litvin, MD. Co-Founder, Chairman, Chief Medical Officer. Dr. Litvin is a graduate of The Hebrew University Medical School in Jerusalem. He completed his residency at the Meir Medical Center in Kfar Saba. He worked as a fellow for two years, specializing in retinal surgery, and completed three years of post-graduate studies in

CORNEAT VISION

CorNeat Vision leverages synthetic biology to introduce implants that address unresolved ophthalmic challenges in the areas of corneal blindness, ocular trauma, glaucoma, hypotony and epiphora (tearing). As of today, we have successfully developed an artificial cornea and an artificial sclera.

NEWS - CORNEAT

Tune in to this episode of The Joel Show and listen to an interview with Dr. Gilad Litvin and Almog Aley-Raz, speaking in greater detail about CorNeat Vision’s

CORNEAT KPRO

The CorNeat KPro is an artificial cornea, Keratoprosthesis, which provides a long-lasting medical solution for corneal blindness, pathology and injury. CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue.

TEAM - CORNEAT

Our mission is to promote health and equality worldwide through innovative biomimetic medical solutions that are widely accessible. Our goal at CorNeat Vision is to innovate and grow, as well as leverage the power of partnerships to introduce biomimetic implants that aim to permanently resolve medical and surgical challenges in diversified therapeutic fields.

CORNEAT EVERPATCH

The CorNeat EverPatch (scleral patch) is the first inert, synthetic and non-degradable tissue substitute for use in ophthalmic surgeries. CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma

drainage devices.

COMMERCIAL PARTNERS

Corneat Vision is establishing its global presence through selected authorized distributors. Our distribution partners shall provide high standards of service, customer support and regulatory compliance. If your company would like to become our distributor, please take our survey and leave your contact details using the link below. CORNEAT KPRO ANIMATION I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication channels R. DOYLE STULTING, MD, PHD Dr. Stulting is the Co-Founder of the Stulting Research Center, a pioneer in corneal disease research and LASIK, and serves as the Director of Corneal Disease and Research at Woolfson Eye Institute. With an illustrious career spanning more than 30 years, his basic research efforts have created deeper understanding of the mechanisms of corneal transplant rejection, herpetic ocular disease and EDWARD J. HOLLAND, MD Edward J. Holland, M.D. is the Director of Cornea Services at Cincinnati Eye Institute and Professor of Ophthalmology at the University of Cincinnati. He attended the Loyola-Stritch School of Medicine in Chicago and trained in Ophthalmology at the University of Minnesota. Dr. Holland completed a fellowship in Cornea and External Disease at the University of Iowa, and a second fellowship in

GILAD LITVIN, MD

Gilad Litvin, MD. Co-Founder, Chairman, Chief Medical Officer. Dr. Litvin is a graduate of The Hebrew University Medical School in Jerusalem. He completed his residency at the Meir Medical Center in Kfar Saba. He worked as a fellow for two years, specializing in retinal surgery, and completed three years of post-graduate studies in

CORNEAT VISION

CorNeat Vision leverages synthetic biology to introduce implants that address unresolved ophthalmic challenges in the areas of corneal blindness, ocular trauma, glaucoma, hypotony and epiphora (tearing). As of today, we have successfully developed an artificial cornea and an artificial sclera.

OUR TECHNOLOGY & IP

Our Technology. CorNeat Vision’s core technology consists of a biocompatible non-degradable biomimetic material that imitates the micro-structure of the human extracellular matrix (ECM) which is the collagen mesh that provides the structural and biochemical support to surrounding cells. Unlike scaffolds and other collagen matrices which

are

CORNEAT KPRO

The CorNeat KPro is an artificial cornea, which provides a long-lasting medical solution for corneal blindness, pathology and injury. The CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue. CORNEAT VISION'S SYNTHETIC CORNEA APPROVED FOR FIRST-IN RA'ANANA, Israel, July 14, 2020 /PRNewswire/ -- The CorNeat KPro, the first synthetic cornea that bio-integrates with the eye wall, received approval to begin a clinical trial at Beilinson Hospital, Israel. The clinical trial, approved by Israel's Ministry of Health, will include 10 corneally blind patients who are not candidates for, or have failed one or more corneal transplantations. CONTACT | CORNEAT VISION | BIOMIMETIC IMPLANTS AND TECHNOLOGY info@corneat.com 4 Hasheizaf St. Raanana, Israel I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication

channels

CORNEAT VISION PARTNERS WITH LIVEU AND ALCON FOR REMOTE CorNeat Vision recently issued a press release, detailing the joint venture between the company, Alcon and LiveU. The companies joined forces due to the travel restrictions enforced by COVID-19, coming up with a solution titled Remote Surgeon Virtual Presence (RSVP). The RSVP enabled initiation of the Canadian clinical site toward first implantations of the CorNeat KPro artificial cornea. CORNEAT KPRO ANIMATION I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication channels EVENTS - CORNEAT VISION The CorNeat KPro is a nanotechnology-based solution which will bring new hope to millions of blind and visually-impaired people DISTRIBUTION APPLICATION SURVEY Distribution Application Survey Kindly complete the distribution application survey to allow CorNeat Vision to evaluate your approach. Please try to respond to all questions.

SEEING AGAIN!

I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication channels

*

*

*

Our Technology

* Our Technology

* Use Cases

* Histology

* IP

*

Our Solutions

* CorNeat KPro

* CorNeat EverPatch

* CorNeat eShunt

* CorNeat gPatch

*

For Physicians

* CorNeat KPro

* CorNeat EverPatch

* CorNeat eShunt

* CorNeat gPatch

*

Commercial Partners

* Distribution Application Survey

*

About Us

* About CorNeat Vision

* Our Mission

* Management Team

* Scientific Advisory Board * Scientific Collaboration * Awards & Accreditations

*

Media Center

* Events

* In the News

*

Contact

* Contact Us

* Subscribe & Register

*

More

BIOMIMETIC IMPLANTS AND TECHNOLOGY

BIOMIMETICS

Biomimetics is the emulation of the models, systems, and elements of nature for the purpose of solving complex human problems.*

​

At CorNeat Vision we harness unique characteristics of microstructures of the human body to develop biomimetic implants which mend and replace damaged tissue, while mimicking its function.

​

Our core platform technology, which was already validated in-vivo, enables permanent implants to bio-mechanically integrate with live tissue without triggering an adverse immune system response.

​

Our platform is a 100% synthetic non-degradable porous material that mimics the micro-structure of the Extracellular Matrix (ECM), the natural biological collagen mesh that provides structural and biochemical support to surrounding cells. When implanted, this material stimulates cellular proliferation leading to progressive

tissue integration.

​

​

This technology enables us to develop implants that are:

​

*

100% synthetic and therefore does not carry disease

*

Effectively bio-integrate and therefore heal faster

*

Do not rely on any type of harvested tissue and therefore scalable

​

CorNeat Vision’s platform technology has dozens of applications across diversified therapeutic fields. The platform material can be produced in various 2D and 3D forms enabling the following functions:

​

*

Physical attachment of implants to tissue

*

Concealment of implants & sensors

*

Soft tissue repair and permanent reinforcement

*

Fabrication of membranes and tissue barriers CorNeat Vision’s initial set of novel implants combine its biomimetic technology with innovative ideas to effectively address unmet needs in the areas of ophthalmology and periodontology. We are currently expanding our IP portfolio to additional fields of medicine.

Read More

*Vincent, Julian F. V.; et al. (22 August 2006). "Biomimetics: its practice and theory". Journal of the Royal Society Interface. 3 (9): 471–482. doi:10.1098/rsif.2006.0127. PMC 1664643. PMID 16849244.

CORNEAT EVERPATCH

SYNTHETIC TISSUE SUBSTITUTE

For Patients

For Physicians

CORNEAT KPRO

SYNTHETIC CORNEA

For Patients

For Physicians

CORNEAT ESHUNT

GLAUCOMA SHUNT

For Patients

For Physicians

CORNEAT GPATCH

SYNTHETIC REINFORCEMENT PATCH

For Patients

For Physicians

OUR MISSION: HARNESS BIOMIMICRY FOR IMPROVING HEALTH Our mission is to promote health and equality worldwide through innovative biomimetic  medical solutions that are widely accessible.

​

Our goal at CorNeat Vision is to innovate, collaborate and grow in our efforts to introduce biomimetic implants with the aim of permanently resolving medical and surgical challenges in diversified therapeutic

fields.

​

We promote permanent solutions to medical problems through an active learning process, placing the physician's ease-of-use as a top

priority.

ABOUT CORNEAT VISION CorNeat Vision was established in December 2015 with the goal of developing, producing and introducing to global markets a scalable artificial solution for global corneal blindness, while eliminating the dependency on donor tissue.

​

Impressed with our pre-clinical trials, which demonstrated progressive and seamless tissue integration of our biomimetic material, the company's advisory board suggested replacing the use  of tectonic tissue grafts with our material in other ophthalmic surgical procedures. Realizing the potential of our platform technology, we registered IP for additional devices in the ophthalmic space.

​

In order to fully exploit the business potential of our technology and to maximize its impact on human health, we have expanded our IP and product portfolio and introduced solutions in additional fields of medicine. Our first such product is aimed at permanently resolving gingival recession and replacing the current use of degradable tissue

grafts.

​

Our first two products, the CorNeat EverPatch (synthetic tissue substitute) and the CorNeat KPro (synthetic cornea), are in clinical trials and expected to receive initial marketing approval in 2022 and 2023, respectively.

info@corneat.com

Visit us at

4 HaSheizaf St.

Ra'anana, Israel

*

*

Home

Our Technology

Our Solutions

For Physicians

Commercial Partners

About Us

Media Center

Contact

​

Terms of Use

Join Our Mailing List

>

I acknowledge and agree to CorNeat Vision'sPrivacy Policy I agree to receive marketing communications, updates, newsletters and any other offers from CorNeat Vision, by email, SMS, MMS and any other communication channels Thanks for submitting!